MedTrace Logo

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

NCT06441084 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-06-04

No results posted yet for this study

Summary

A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.

Conditions

Interventions

BIOLOGICAL

NCR300 injection

Subjects will receive at least 1 cycle of NCR300 injection.

Sponsors & Collaborators

  • Beijing Friendship Hospital

    collaborator OTHER

  • Nuwacell Biotechnologies Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhao Wang, Doctor · Capital Medical University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2028-12-31
Completion
2031-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441084 on ClinicalTrials.gov